导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.51% | 1205/4773 |
| 近一周 | -2.63% | 2726/5462 |
| 近一月 | -5.03% | 2992/5421 |
| 近一季 | -8.59% | 2862/5209 |
| 近半年 | -5.44% | 2866/4920 |
| 近一年 | 10.14% | 1027/4366 |
| 近两年 | 82.77% | 771/2954 |
| 近三年 | 46.12% | 607/2253 |
| 成立以来 | 115.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.27% 986/4961 |
20.18% 1247/5312 |
- - |
- - |
| 2025 | 34.61% 1031/4813 |
2.95% 1232/3635 |
2.29% 1678/4076 |
26.16% 1358/4524 |
1.32% 1420/4813 |
| 2024 | 9.06% 1498/3463 |
-2.57% 1382/2808 |
-5.09% 1642/3014 |
17.15% 1259/3129 |
0.68% 1181/3463 |
| 2023 | -4.57% 686/2656 |
8.23% 480/2280 |
-3.74% 886/2385 |
-3.98% 1031/2515 |
-4.60% 1111/2655 |
| 2022 | -17.29% 570/2207 |
-13.60% 794/1919 |
3.45% 1150/2016 |
-10.17% 359/2113 |
3.02% 784/2208 |
| 2021 | 25.13% 113/1822 |
-0.16% 335/1255 |
12.41% 335/1330 |
6.82% 209/1466 |
4.37% 336/1822 |
| 2020 | 33.61% 453/1250 |
-5.48% 424/1028 |
19.59% 296/1067 |
11.98% 412/1164 |
5.56% 780/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证500ETF VS. 长安沪深300非周期A(740101) |